Zoetis Inc (ZTS) To Go Ex-Dividend on January 16th

Zoetis Inc (NYSE:ZTS) declared a quarterly dividend on Friday, December 13th, Wall Street Journal reports. Stockholders of record on Friday, January 17th will be paid a dividend of 0.20 per share on Tuesday, March 3rd. This represents a $0.80 annualized dividend and a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, January 16th. This is an increase from Zoetis’s previous quarterly dividend of $0.16.

Zoetis has raised its dividend payment by an average of 28.2% per year over the last three years and has raised its dividend every year for the last 5 years. Zoetis has a dividend payout ratio of 22.1% indicating that its dividend is sufficiently covered by earnings. Analysts expect Zoetis to earn $3.98 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 20.1%.

Shares of ZTS opened at $136.51 on Tuesday. The firm has a market cap of $64.57 billion, a P/E ratio of 43.61, a P/E/G ratio of 2.94 and a beta of 0.81. The stock has a 50 day simple moving average of $128.14 and a two-hundred day simple moving average of $123.19. The company has a debt-to-equity ratio of 2.47, a current ratio of 4.39 and a quick ratio of 3.02. Zoetis has a 1 year low of $82.26 and a 1 year high of $136.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.88 by $0.06. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.58 billion. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $0.83 earnings per share. On average, equities analysts anticipate that Zoetis will post 3.6 earnings per share for the current year.

In related news, EVP Clinton A. Jr. Lewis sold 6,123 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $124.93, for a total transaction of $764,946.39. Following the completion of the transaction, the executive vice president now owns 34,027 shares in the company, valued at $4,250,993.11. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Andrew Fenton sold 12,705 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $120.30, for a total value of $1,528,411.50. Following the completion of the sale, the executive vice president now directly owns 21,530 shares of the company’s stock, valued at approximately $2,590,059. The disclosure for this sale can be found here. In the last three months, insiders sold 123,917 shares of company stock worth $14,797,192. Insiders own 0.29% of the company’s stock.

Several equities analysts recently commented on the stock. Bank of America reaffirmed a “hold” rating and set a $125.00 target price on shares of Zoetis in a report on Thursday, December 5th. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $142.00 price target for the company in a research report on Thursday, December 26th. Raymond James initiated coverage on Zoetis in a research note on Thursday, January 9th. They set a “market perform” rating on the stock. Morgan Stanley lifted their price objective on Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a report on Monday, September 30th. Finally, ValuEngine lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Eight equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Zoetis has an average rating of “Buy” and a consensus price target of $127.47.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: What is Liquidity?

Dividend History for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.